| Literature DB >> 24964077 |
Sunao Shoji1, Akiko Tonooka, Akio Hashimoto, Masahiko Nakamoto, Tetsuro Tomonaga, Mayura Nakano, Haruhiro Sato, Toshiro Terachi, Junki Koike, Toyoaki Uchida.
Abstract
Avascular areas on contrast-enhanced magnetic resonance imaging have been considered to be areas of localized prostate cancer successfully treated by high-intensity focused ultrasound. However, the optimal timing of magnetic resonance imaging has not been discussed. The thermal effect of high-intensity focused ultrasound is degraded by regional prostatic blood flow. Conversely, the mechanical effect of high-intensity focused ultrasound (cavitation) is not affected by blood flow, and can induce vessel damage. In this series, the longitudinal change of blood flow on contrast-enhanced magnetic resonance imaging was observed from postoperative day 1 to postoperative day 14 in 10 patients treated with high-intensity focused ultrasound. The median rates of increase in the non-enhanced volume of the whole gland, transition zone and peripheral zone from postoperative day 1 to postoperative day 14 were 36%, 39%, and 34%, respectively. In another pathological analysis of the prostate tissue of 17 patients immediately after high-intensity focused ultrasound without neoadjuvant hormonal therapy, we observed diffuse coagulative degeneration and partial non-coagulative prostate tissue around arteries with vascular endothelial cell detachment. These observations on contrast-enhanced magnetic resonance imaging support a time-dependent change of the blood flow in the prostate treated with high-intensity focused ultrasound. Additionally, our pathological findings support the longitudinal changes of these magnetic resonance imaging findings. Further large-scale studies will investigate the most appropriate timing of contrast-enhanced magnetic resonance imaging for evaluation of the effectiveness of high-intensity focused ultrasound for localized prostate cancer.Entities:
Keywords: blood flow; high-intensity focused ultrasound; magnetic resonance imaging; pathology; prostate cancer
Mesh:
Year: 2014 PMID: 24964077 DOI: 10.1111/iju.12515
Source DB: PubMed Journal: Int J Urol ISSN: 0919-8172 Impact factor: 3.369